Healthcare > Pharmaceuticals & Biotechnology
•770 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (770)
%
| Company | Market Cap | Price |
|---|---|---|
|
Immunology Therapeutics: Aclaris develops therapies for immune-inflammatory diseases (e.g., atopic dermatitis, psoriasis) and autoimmune conditions.
|
$207.90M |
$1.90
-1.04%
|
|
CRGX directly developed autologous CAR T-cell therapies (firi-cel) and related cell-therapy programs (CRG-23), which are core, direct products.
|
$206.13M |
$4.47
|
|
ProQR's core Axiomer platform is a gene therapy–style RNA editing technology with clinical programs AX-0810 and AX-2402.
|
$203.04M |
$2.41
-3.98%
|
|
ASMB's core business is the discovery and development of small-molecule antiviral therapies for HSV genital herpes, HDV, and HBV, representing a distinct antiviral small-molecule therapeutics category.
|
$202.47M |
$26.51
-1.67%
|
|
TARA-2.00 is a cell therapy platform (OK-432) developed by Protara; a core product category is cell therapy.
|
$201.40M |
$5.22
-8.42%
|
|
Rocky Brands provides Contract Manufacturing services, including third-party production and Navy orders.
|
$198.32M |
$26.58
-4.87%
|
|
Core product: OmniAb's antibody discovery platform (Biological Intelligence) enabling generation of human antibodies via engineered transgenic animals and AI/ML.
|
$197.57M |
$1.61
-11.26%
|
|
Company directly develops and commercializes monoclonal antibody therapeutics, including PEMGARDA, and a pipeline candidate (VYD2311).
|
$195.54M |
$1.63
+9.40%
|
|
Heron Therapeutics' main products are oncology supportive-care drugs (CINVANTI, SUSTOL) and NK1 receptor antagonist APONVIE for post-operative nausea/vomiting, aligning with Biotech - Oncology.
|
$195.28M |
$1.28
-2.29%
|
|
LOQTORZI is a monoclonal antibody PD-1 inhibitor and the lead product, representing direct monoclonal antibody therapeutics.
|
$193.61M |
$1.67
-9.73%
|
|
BioAge's lead programs (BGE-102 and APJ agonists) are oral small-molecule therapeutics for obesity/metabolic disease, directly describing their product category.
|
$191.80M |
$5.35
-2.01%
|
|
Genelux develops oncolytic viral immunotherapies for cancer, anchored by Olvi-Vec, fitting Biotech - Oncology.
|
$191.32M |
$5.07
-7.82%
|
|
CDMO services are a core outsourced drug development function, aligning with Contract Research Organizations.
|
$191.30M |
$11.04
-8.08%
|
|
GPS and SLS009 are oncology-focused therapeutics developed by SELLAS Life Sciences.
|
$190.58M |
$1.91
-1.04%
|
|
CRBP's core strategy focuses on oncology therapies, including targeted antibody–drug conjugates and immunotherapy approaches.
|
$190.16M |
$15.54
-2.08%
|
|
Protalix develops recombinant protein therapies for rare diseases (Elelyso and Elfabrio) and has a pipeline focused on rare renal indications.
|
$188.17M |
$2.36
+5.36%
|
|
Core business is building off-the-shelf cell therapies (CAR T and CAR NK) derived from iPSCs for multiple indications.
|
$187.42M |
$1.64
+0.31%
|
|
Lead programs are orally bioavailable small-molecule degraders (MonoDACs/BiDACs), aligning with Oral Small Molecule Therapeutics.
|
$171.84M |
$2.42
-6.20%
|
|
Eledon's direct product focus is tegoprubart, an immunology therapeutic (anti-CD40L antibody) in transplantation, placing the company squarely in Immunology Therapeutics.
|
$171.26M |
$2.86
+0.35%
|
|
Emrosi is an oral small molecule therapeutic for rosacea, representing Journey Medical's core product avenue.
|
$169.83M |
$7.29
+0.41%
|
|
Company is a biotech focused on oncology immunotherapies leveraging a platform (AMP) for cancer treatment.
|
$169.25M |
$10.58
-5.11%
|
|
Biotech - Cell Therapy: cell therapy manufacturing and modification enabled by MaxCyte's platform.
|
$167.98M |
$1.66
+5.06%
|
|
CGEN's core business is immuno-oncology, developing antibody-based therapies (e.g., COM701) and advancing IO assets.
|
$165.64M |
$1.85
-5.13%
|
|
Innate Pharma's core pipeline is oncology-focused, including monoclonal antibodies and antibody-based immunotherapies (lacutamab and monalizumab).
|
$164.36M |
$2.03
+2.53%
|
|
Company focuses on oncology delivery technologies (PEDD) and has an investigational immunotherapy asset (nelitolimod), placing it in Oncology/Biotech domains.
|
$163.46M |
$4.32
-2.26%
|
|
CytoDyn's leronlimab is a CCR5-targeting biologic being developed for oncology, fitting Biotech - Oncology.
|
$163.45M |
$0.27
+2.97%
|
|
Company's core platform is gene therapy using zinc finger and ZFR technologies, a direct gene therapy product category.
|
$156.76M |
$0.67
-10.35%
|
|
Ionis partnership (donidalorsen and olezarsen) targets rare diseases in Canada with meaningful profitability potential.
|
$155.87M |
$3.39
+0.89%
|
|
TNX-102 SL is a non-opioid, small-molecule therapeutic formulated as a sublingual tablet for fibromyalgia.
|
$155.21M |
$21.19
-4.46%
|
|
PepGen's core differentiator is the Enhanced Delivery Oligonucleotide (EDO) platform, a drug-delivery platform for oligonucleotide therapies.
|
$154.28M |
$4.71
-3.78%
|
|
Lead pipeline SER-155/SER-147 are cultivated live biotherapeutics, a cell-therapy modality.
|
$153.34M |
$18.77
-3.17%
|
|
Actuate Therapeutics is a biotech company focused on oncology, developing cancer therapies (elraglusib) with clinical-stage programs.
|
$152.84M |
$7.79
-4.06%
|
|
The company focuses on neuropsychiatric drug development for disorders such as MDD, bipolar depression, TRD, and schizophrenia.
|
$152.69M |
$5.64
-6.47%
|
|
Nkarta's lead candidate NKX019 is an allogeneic CAR NK-cell therapy, directly aligning with the Cell Therapy product category.
|
$151.14M |
$2.13
-2.29%
|
|
Direct oncology biotech focus; Cardiff Oncology's lead asset is an oncology drug (onvansertib).
|
$147.02M |
$2.21
-7.14%
|
|
Avalo directly develops monoclonal antibodies targeting immune dysregulation (e.g., AVTX-9.00), placing the business in Immunology Therapeutics.
|
$145.09M |
$13.40
+3.47%
|
|
Simufilam is an oral small molecule therapeutic being developed as the company's lead drug candidate.
|
$144.44M |
$2.90
-2.84%
|
|
NXP900 is an oral small-molecule therapeutic (kinase inhibitor) directly developed by NVCT.
|
$140.86M |
$5.96
-0.33%
|
|
RECELL-based autologous cell suspension therapy aligns with Biotech - Cell Therapy as a core regenerative medicine product.
|
$140.50M |
$1.00
|
|
Atossa's lead candidate targets metastatic breast cancer, a core oncology focus in biotech/pharma.
|
$139.50M |
$1.08
-7.69%
|
|
Anixa's core focus is oncology-biotech with direct development of cancer therapies, fitting Biotech - Oncology.
|
$139.47M |
$4.33
-12.35%
|
|
RECELL is an autologous skin-cell suspension therapy, aligning with Biotech - Cell Therapy as a cell-based regenerative treatment.
|
$135.87M |
$5.14
-6.72%
|
|
Direct focus on rare disease therapies under the Biotech - Rare Diseases category (govorestat and related ARI programs).
|
$133.12M |
$0.94
-9.59%
|
|
Tevogen's core offering is off-the-shelf, precision T cell therapies using the ExacTcell platform, i.e., cell therapy products.
|
$131.50M |
$0.72
-3.36%
|
|
The HA platform enables localized, potentially controlled-release regenerative therapies.
|
$131.49M |
$9.12
-1.51%
|
|
Nimacimab is a monoclonal antibody therapeutic targeting CB1 for obesity, representing Skye's core product.
|
$127.35M |
$3.96
-3.77%
|
|
Direct product category: bispecific antibodies (PD-L1xVEGF) developed/distributed by the company.
|
$126.15M |
$19.23
-8.43%
|
|
Company focuses on oncology DARPin therapeutics as a core business line, including lead AML/MDS program (MP0533) and RDTs.
|
$126.14M |
$3.80
+1.06%
|
|
Provides ODM/contract manufacturing services for nicotine vaping devices from its Malaysia facility.
|
$125.72M |
$2.20
-7.95%
|
|
Company is advancing TCR-T cell therapies, a form of cell therapy for cancer.
|
$125.07M |
$2.21
+0.45%
|
|
Cabaletta's lead product rese-cel is a CD19-directed CAR T cell therapy, i.e., a cell therapy product in biotech.
|
$123.81M |
$2.44
-1.61%
|
|
EB613 and other pipeline candidates are peptide therapeutics administered orally, fitting the Peptide Therapeutics category.
|
$120.45M |
$2.65
+6.00%
|
|
IKT-001Pro is an oral small-molecule prodrug therapy (Imatinib derivative) being developed for PAH.
|
$120.43M |
$1.62
|
|
Surrozen' core ophthalmology-focused ophthalmic drug programs (SZN-8141/8143/113) target retinal diseases and corneal conditions.
|
$117.88M |
$13.77
-1.10%
|
|
Core focus on neuropsychiatric drug development using a non-systemic intranasal pherine platform for CNS disorders (e.g., fasedienol for SAD).
|
$117.51M |
$4.03
-4.73%
|
|
Core business pivot to an AAV-based gene therapy platform with lead programs for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$116.94M |
$1.96
-2.97%
|
|
Lead asset azenosertib is an oncology-focused small molecule targeting WEE1, aligning with Biotech - Oncology.
|
$115.84M |
$1.59
-0.93%
|
|
Direct product: tebipenem HBr is an oral small-molecule therapeutic for complicated urinary tract infections, representing Spero Therapeutics' core asset.
|
$114.62M |
$2.05
+1.99%
|
|
Armata develops bacteriophage-based therapeutics for bacterial infections, aligning with Immunology Therapeutics.
|
$112.92M |
$3.12
+0.65%
|
|
Directly develops a gene therapy product (Ixo-vec) for an ocular indication, using AAV-based delivery.
|
$112.60M |
$5.39
+0.09%
|
|
Direct Alzheimer's disease therapeutics product line (ZUNVEYL) targets mild-to-moderate Alzheimer's disease.
|
$112.46M |
$7.02
-7.99%
|
|
Oncology diagnostics pipeline (DetermaIO, DetermaCNI) represents core oncology biotech offerings.
|
$111.25M |
$3.89
+2.37%
|
|
Development of a GMP-compliant manufacturing factory through Nika Europe signals in-house pharmaceutical production capacity, consistent with contract manufacturing capabilities.
|
$109.82M |
$0.32
|
|
SL-325 is a high-affinity monoclonal antibody targeting DR3, representing the core antibody therapeutic lead.
|
$109.21M |
$2.28
+1.33%
|
|
Agenus' core oncology program centers on botensilimab (BOT) and balstilimab (BAL), a differentiated immuno-oncology therapy portfolio.
|
$108.84M |
$3.97
-6.81%
|
|
SGT-610 targets Gorlin Syndrome, a rare genetic disease, aligning with the Biotech - Rare Diseases theme.
|
$108.62M |
$38.99
-2.48%
|
|
MGX is developing a gene therapy/gene editing platform (metagenomics-derived toolbox) with in vivo and ex vivo capabilities.
|
$106.91M |
$2.86
-8.04%
|
|
Achieve Life Sciences' direct product is cytisinicline, an oral small-molecule therapeutic for nicotine dependence, which corresponds to the 'Oral Small Molecule Therapeutics' investable theme.
|
$106.83M |
$3.08
-7.23%
|
|
Core focus on antibody-based oncology therapeutics (bispecifics and ADCs) directly aligns with Biotech - Oncology.
|
$106.62M |
$1.69
-4.52%
|
|
Etripamil is a cardiovascular drug (calcium channel blocker) aimed at PSVT and AFib-RVR, making Cardiovascular Drugs the core product category.
|
$106.39M |
$1.99
-5.24%
|
|
HilleVax is a vaccine-focused biotech developing norovirus vaccines (HIL-214.00 and HIL-216.00), directly aligning with the Vaccines tag.
|
$104.79M |
$2.09
|
|
Lead asset sabirnetug is a monoclonal antibody therapeutic targeting soluble AßOs in Alzheimer's disease; qualifies as Monoclonal Antibody Therapeutics.
|
$104.79M |
$1.73
-3.35%
|
|
ELYXYB (celecoxib oral solution) and GLOPERBA (colchicine oral solution) are oral small-molecule therapeutics directly produced and marketed by Scilex.
|
$103.79M |
$14.93
-15.27%
|
|
EUDA is pivoting to stem-cell and regenerative medicine, including iPSC-based cell therapies, making Cell Therapy a core current product/technology focus.
|
$102.23M |
$2.86
+4.38%
|
|
COYA's autologous Treg cell therapy program (COYA 101) and exosome-based strategies place it in the cell therapy space.
|
$101.52M |
$6.07
-3.04%
|
|
FB102 is a therapeutic monoclonal antibody targeting CD122 for autoimmune diseases, representing Forte Biosciences' core immunology-focused drug development program.
|
$100.53M |
$15.27
+0.79%
|
|
ALXO's lead and preclinical programs include antibody-drug conjugates (ADC), notably ALX2004 and evorpacept-based combos.
|
$99.94M |
$1.76
-5.88%
|
|
Lead asset CBP-201 is a monoclonal antibody targeting IL-4Rα, placing CNTB's direct product category in Monoclonal Antibody Therapeutics.
|
$98.90M |
$1.74
-17.77%
|
|
Oramed's primary business is developing and commercializing pharmaceutical/biotech therapies with a focus on oral protein delivery (ORMD-0801 for insulin), aligning with the Large Cap Pharma / Pharmaceuticals & Biotechnology investable theme.
|
$98.45M |
$2.41
+1.26%
|
|
Lead product candidate is a small molecule therapeutic (selonabant) and the company developing oral small molecule therapeutics, with a strategic IV formulation for pediatric cannabis toxicity.
|
$95.32M |
$2.32
+2.20%
|
|
Efzofitimod is an immunomodulatory biologic addressing inflammation and fibrosis, placing ATYR in Immunology Therapeutics.
|
$94.34M |
$1.06
-0.93%
|
|
INOVIO's core DNA Medicines platform and SynCon/CELLECTRA approach represent its primary gene therapy technology for delivering therapeutic proteins in vivo.
|
$94.25M |
$2.57
-1.91%
|
|
Atara's lead program tab-cel (Ebvallo) is a allogeneic cell therapy, i.e., a cell-based immunotherapy.
|
$93.18M |
$15.09
-3.45%
|
|
Pelareorep is a cancer-focused oncolytic virus immunotherapy, which directly constitutes the company's core oncology product.
|
$92.49M |
$1.20
-5.51%
|
|
PLRX's PLN-101095 is an oncology program targeting ICI-refractory solid tumors, making Biotech - Oncology a core segment.
|
$91.47M |
$1.49
-2.61%
|
|
Direct focus on oncology; Champions Oncology specializes in oncology translational research and PDX-based models.
|
$90.10M |
$6.54
-0.46%
|
|
Develops monoclonal antibody therapeutics (SAFEbody/POWERbody platforms) for cancer.
|
$86.33M |
$1.95
-1.52%
|
|
Burning Rock Biotech operates in oncology biotechnology with MRD and MCED testing, a core oncology diagnostics business.
|
$86.30M |
$8.36
-4.46%
|
|
Immunic's pipeline consists of oral small-molecule therapeutics (IMU-838 and IMU-856) targeting immunology/autoimmune diseases, representing the core product category.
|
$86.09M |
$0.90
-2.61%
|
|
ATH434 is a small-molecule therapeutic candidate (likely oral) targeting neurodegenerative pathways, representing Alterity's core product.
|
$85.62M |
$0.01
|
|
Pocono Pharmaceuticals' contract manufacturing capabilities, including production of topical/transdermal products, fit the Contract Manufacturing Organization (CMO) category.
|
$83.77M |
$7.51
-4.21%
|
|
Directly developing and marketing an oral small-molecule therapeutic (zervimesine/CT1812) for neurodegenerative diseases, fitting the 'Oral Small Molecule Therapeutics' category.
|
$83.69M |
$1.35
+1.50%
|
|
Vilobelimab is a monoclonal antibody targeting C5a, placing InflaRx in the Monoclonal Antibody Therapeutics category.
|
$81.26M |
$1.38
-4.83%
|
|
CNTX's core product category is T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202).
|
$81.01M |
$0.89
-1.06%
|
|
Fortress's portfolio includes oncology-focused assets (e.g., Mustang Bio's cell therapies and CHKP's oncology programs).
|
$80.13M |
$2.71
-3.56%
|
|
Directly aligns with Adicet's core offering of allogeneic cell-based therapies (gamma delta T cell therapies) as the company focuses on cell therapy products.
|
$80.00M |
$0.97
+5.13%
|
|
Sympazan PharmFilm technology and overall drug-delivery differentiation reflect Drug Delivery Platforms.
|
$79.98M |
$0.83
-4.47%
|
|
DLH provides science R&D support, clinical research-like services, and epidemiology/data analytics akin to Contract Research Organizations.
|
$79.70M |
$5.61
-1.41%
|
|
Core product focus on vaccines (norovirus, COVID-19, avian influenza) using the VAAST oral vaccine platform.
|
$79.22M |
$0.35
-1.41%
|
|
XBiotech markets a proprietary True Human antibody platform used to identify and clone natural human monoclonal antibodies (antibody discovery platform).
|
$77.44M |
$2.54
-3.05%
|
Showing page 5 of 8 (770 total stocks)
Loading industry metrics...
Loading comparison data...
